392 related articles for article (PubMed ID: 33545391)
1. Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH.
Goedeke L; Shulman GI
Mol Metab; 2021 Apr; 46():101178. PubMed ID: 33545391
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease.
Ramanathan R; Ali AH; Ibdah JA
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806284
[TBL] [Abstract][Full Text] [Related]
3. Small Molecule Mitochondrial Uncouplers and Their Therapeutic Potential.
Childress ES; Alexopoulos SJ; Hoehn KL; Santos WL
J Med Chem; 2018 Jun; 61(11):4641-4655. PubMed ID: 29156129
[TBL] [Abstract][Full Text] [Related]
4. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats.
Perry RJ; Zhang D; Zhang XM; Boyer JL; Shulman GI
Science; 2015 Mar; 347(6227):1253-6. PubMed ID: 25721504
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.
Sunny NE; Bril F; Cusi K
Trends Endocrinol Metab; 2017 Apr; 28(4):250-260. PubMed ID: 27986466
[TBL] [Abstract][Full Text] [Related]
6. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease.
Koliaki C; Roden M
Mol Cell Endocrinol; 2013 Oct; 379(1-2):35-42. PubMed ID: 23770462
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
8. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury.
Serviddio G; Bellanti F; Tamborra R; Rollo T; Capitanio N; Romano AD; Sastre J; Vendemiale G; Altomare E
Gut; 2008 Jul; 57(7):957-65. PubMed ID: 18308829
[TBL] [Abstract][Full Text] [Related]
9. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
Barchetta I; Cimini FA; Cavallo MG
Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
12. Exploring the therapeutic potential of mitochondrial uncouplers in cancer.
Shrestha R; Johnson E; Byrne FL
Mol Metab; 2021 Sep; 51():101222. PubMed ID: 33781939
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial oxidative injury: a key player in nonalcoholic fatty liver disease.
Dornas W; Schuppan D
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G400-G411. PubMed ID: 32597705
[TBL] [Abstract][Full Text] [Related]
14. From fatty liver to fibrosis: a tale of "second hit".
Basaranoglu M; Basaranoglu G; Sentürk H
World J Gastroenterol; 2013 Feb; 19(8):1158-65. PubMed ID: 23483818
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
[TBL] [Abstract][Full Text] [Related]
16. The emerging significance of mitochondrial targeted strategies in NAFLD treatment.
Zhang T; Nie Y; Wang J
Life Sci; 2023 Sep; 329():121943. PubMed ID: 37454757
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
Pettinelli P; Obregón AM; Videla LA
Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
Firneisz G
World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
[TBL] [Abstract][Full Text] [Related]
19. Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes.
Gancheva S; Kahl S; Pesta D; Mastrototaro L; Dewidar B; Strassburger K; Sabah E; Esposito I; Weiß J; Sarabhai T; Wolkersdorfer M; Fleming T; Nawroth P; Zimmermann M; Reichert AS; Schlensak M; Roden M
Diabetes Care; 2022 Apr; 45(4):928-937. PubMed ID: 35113139
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
